The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Arnon Goldberg, Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01686048
First received: September 12, 2012
Last updated: October 6, 2015
Last verified: October 2015
  Purpose

Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants has been detected in several locations in Israel.

In the proposed study, patients referred for routine allergic evaluation will also be skin tested with Ambrosia allergens, in addition to their regular prick skin tests with all other airborne allergens.


Condition
Allergic Rhinitis
Asthma
Allergic Conjunctivitis
Atopic Dermatitis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Estimated Enrollment: 120
Study Start Date: April 2015
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients refered for allergic evaluation
Criteria

Inclusion Criteria:

  • Patients with allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis who undergo prick skin tests with airborne allergens
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01686048

Locations
Israel
Arnon Goldberg, M.D., Allergy and Clinical Immunology Unit, Meir Medical Center
Kfar-Saba, Israel, 44281
Sponsors and Collaborators
Meir Medical Center
  More Information

Responsible Party: Arnon Goldberg, Head, Allergy and Clinical Immunology Unit, Meir Medical Center
ClinicalTrials.gov Identifier: NCT01686048     History of Changes
Other Study ID Numbers: Ambrosia 
Study First Received: September 12, 2012
Last Updated: October 6, 2015
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Asthma
Rhinitis
Dermatitis
Rhinitis, Allergic
Dermatitis, Atopic
Eczema
Conjunctivitis
Conjunctivitis, Allergic
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Conjunctival Diseases
Eye Diseases

ClinicalTrials.gov processed this record on July 26, 2016